IntelliCell Biosciences' Cellular Therapy Treatment Yields Positive Results in Multiple Sclerosis Patients
November 12 2013 - 8:57AM
Marketwired
IntelliCell Biosciences' Cellular Therapy Treatment Yields Positive
Results in Multiple Sclerosis Patients
NEW YORK, NY--(Marketwired - Nov 12, 2013) - IntelliCell
Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company
utilizing adult autologous vascular cells (SVCs) derived from the
blood vessels found in adipose tissue, announced today that it has
supplied its cellular product, stromal vascular fraction cells
("SVFC"), to ReGen Medical PC for the successful treatment of a
patient with Multiple Sclerosis.
It is important to note that by "successful," the company is
declaring that these cells do not cure Multiple Sclerosis, but of
the 19 patients with MS that ReGen Medical has treated using
IntelliCell's technology, each have gained anywhere from good to
significant quality of life improvements.
In almost every case that ReGen treated, as well as in this
case, previous medical history stated the patients' Multiple
Sclerosis had progressively worsened. In the case of this patient
she had undergone seven years of progression since her original
diagnosis. This patient was remitted to the care of Dr. Steven
Victor of ReGen Medical PC, where the patient received six
treatments of ReGen Medical's proprietary SVFC, which includes stem
cells, spaced approximately 3-5 months apart. The results of
the treatment reflected significant improvements to the patient's
quality of living. Prior to any SVFC treatments, the patient
experienced a gradual decline, beginning in 2001, of her vision,
bladder control, and mobility, particularly of the extremities on
her right side. This culminated in her diagnosis of stage IV
multiple sclerosis in 2006. Following the first treatment, the
patient regained use of her previously immobile right leg, and
coupled with more treatments and physical therapy, the patient can
now walk. After her second treatment, the patient noticed more
strength and agility in her previously clenched right hand.
Additionally, with further treatment the patient noted drastically
improved vision in her previously debilitated eye and she regained
bladder control. With each patient ReGen Medical has treated, the
number of treatments has varied between one and six, each patient
experiencing different improvements at various intervals.
Dr. Steven Victor, CEO of IntelliCell Biosciences, commented,
"The patient mentioned in this release, was the first clinical case
we treated for MS with IntelliCell's SVFC technology. If not
for our beneficial treatments, this patient would be restricted to
a wheelchair and lose total sight in one of her
eyes. Previously, this patient had been unsuccessfully treated
at some of the most respected Medical Centers in the country and
received little or no improvement to her symptoms. By
utilizing IntelliCell's paradigm shifting medical solutions, we
have dramatically improved the quality of this patient's
life. IntelliCell is confident that the future of medicine
will entail utilizing cellular therapy for previously unmet
clinical needs, and we expect to establish ourselves as a market
leader in this emerging industry."
Multiple Sclerosis (MS), also known as disseminated sclerosis or
encephalomyelitis disseminata, is an inflammatory disease in which
the insulating covers, called myelinsheaths, of nerve cells in the
brain and spinal cord are damaged. This damage disrupts the ability
of parts of the nervous system to communicate, resulting in a wide
range of signs and symptoms, including physical, mental, and
sometimes psychiatric problems. MS takes several forms, with new
symptoms either occurring in isolated attacks (relapsing forms) or
building up over time (progressive forms). Between attacks,
symptoms may go away completely; however, permanent neurological
problems often occur, especially as the disease advances.
About IntelliCell Biosciences IntelliCell is a pioneering
regenerative medicine company focused on the expanding regenerative
medical markets using adult autologous stromal vascular fraction
cells (SVFCs) derived from the blood vessels in the adult adipose
tissue. IntelliCell Biosciences has developed its own patented
technology and protocol to separate adult autologous vascular cells
from adipose tissue without the use of enzymes. IntelliCell will
also be seeking to develop technology-licensing agreements with
technology developers, universities, and international business
entities.
Forward-LookingStatements Certain statements set forth in this
press release constitute "forward-looking statements."
Forward-looking statements include, without limitation, any
statement that may predict, forecast, indicate, or imply future
results, performance or achievements, and may contain the words
"estimate," "project," "intend," "forecast," "anticipate," "plan,"
"planning," "expect," "believe," "will likely," "will reach," "will
change," "will soon," "should," "could," "would," "may," "can" or
words or expressions of similar meaning. Such statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause the company's actual results and
financial position to differ materially from those included within
the forward-looking statements. Forward-looking statements involve
risks and uncertainties, including those relating to the Company's
ability to grow its business. Actual results may differ materially
from the results predicted and reported results should not be
considered as an indication of future performance. The potential
risks and uncertainties include, among others, the Company's
limited operating history, the limited financial resources,
domestic or global economic conditions, activities of competitors
and the presence of new or additional competition, and changes in
Federal or State laws. More information about the potential factors
that could affect the Company's business and financial results is
included in the Company's filings, available via the United States
Securities and Exchange Commission.
Contact: IntelliCell Biosciences, Inc. Investor Relations Anna
Rhodes Email Contact (646) 576-8308